GSK invests more than USD 800 million: JPMorgan targets GSK stock at 1,700 pence

Published on 10/12/2026 at 09:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pennsylvania plan tops USD 800 million and creates 300 jobs. GSK stock approaches results after GBP 8.41 billion second-quarter revenue.

Key points in brief

GSK announced a Pennsylvania investment of more than USD 800 million on October 9, 2026.
The project is linked to 300 new jobs and expands GSK's biopharma presence.
Second-quarter 2026 revenue reached GBP 8.41 billion, up 5.30 percent year over year.
JPMorgan kept a 1,700 pence Underweight target ahead of third-quarter results.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK (ISIN GB00BN7SWP63) had announced an investment of more than USD 800 million in Pennsylvania on October 9, 2026, while JPMorgan kept a 1,700 pence Underweight target for GSK stock. Global Banking and Finance reported that the project is expected to create 300 jobs, and FinanzNachrichten carried JPMorgan's October 1, 2026 analyst note.

Three dated GSK developments

On December 31, 2025, GSK's annual revenue stood at GBP 32.67 billion, up 4.11 percent from GBP 31.38 billion, according to Stock Analysis. On June 30, 2026, revenue reached GBP 8.41 billion in the second quarter, up 5.30 percent year over year. On October 9, 2026, the Pennsylvania plan lifted the announced investment above USD 800 million and added the 300-job commitment.

What does the investment change?

The Pennsylvania project gives the company a concrete manufacturing and research expansion figure alongside its latest operating performance. The second-quarter revenue increase to GBP 8.41 billion was paired with net income of GBP 553.00 million and operating profit of GBP 481.00 million, according to the current financial data for the period ended June 30, 2026.

The contrast matters for the stock narrative. GSK is committing more than USD 800 million to capacity and jobs while JPMorgan's 1,700 pence target remains Underweight, with analyst Zain Ebrahim expecting a solid third quarter but little change in market expectations, as FinanzNachrichten reported on October 1, 2026.

Results date sets the next marker

GSK's next reported results are scheduled for October 28, 2026, according to Stock Analysis. That date will put the Pennsylvania investment beside second-quarter revenue growth and the first full quarter of current strategic execution.

The further course of trading is shown by the continuously updated real-time quote of GSK stock.